Copyright
©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. May 28, 2013; 19(20): 3124-3129
Published online May 28, 2013. doi: 10.3748/wjg.v19.i20.3124
Published online May 28, 2013. doi: 10.3748/wjg.v19.i20.3124
Risk factors for proton pump inhibitor refractoriness in Chinese patients with non-erosive reflux disease
Xiao-Ping Niu, Zhen Han, Shao-Fen Liu, Chi-Yi He, Guo-Zheng Zhang, Wan-Chun Wu, Department of Gastroenterology, Yijishan Hospital, Wannan Medicine College, Wuhu 241001, Anhui Province, China
Bao-Ping Yu, Yun-Dong Wang, Department of Gastroenterology, Renmin Hospital, Wuhan University, Wuhan 430060, Hubei Province, China
Author contributions: Yu BP designed and supervised the study; Han Z instructed the study; Niu XP conceived and designed the study, collected and compiled the patient data, performed the scale survey, wrote the manuscript and gave final approval of the version to be published; Wang YD and Liu SF performed the scale survey and the questionnaire on patient general status and lifestyle; He CY compiled the data and performed the statistical analysis; Wu WC and Zhang GZ collected the cases and enrolled the patients.
Correspondence to: Bao-Ping Yu, MD, Department of Gastroenterology, Renmin Hospital, Wuhan University, No. 99 Zhangzhidong Road, Wuchang District, Wuhan 430060, Hubei Province, China. baopingyu@yahoo.cn
Telephone: +86-27-88041911 Fax: +86-27-88042292
Received: January 14, 2013
Revised: March 20, 2013
Accepted: April 9, 2013
Published online: May 28, 2013
Processing time: 133 Days and 11 Hours
Revised: March 20, 2013
Accepted: April 9, 2013
Published online: May 28, 2013
Processing time: 133 Days and 11 Hours
Core Tip
Core tip: Non-erosive reflux disease (NERD) is significantly more refractory to proton pump inhibitor (PPI) treatment than erosive esophagitis is, although the reason is unclear at present. Here, we investigated the risk factors for refractoriness to PPI treatment in patients with NERD. Our results demonstrate that some NERD patients are refractory to standard doses of PPIs and have a lower quality of life. Residual symptoms are associated with psychological distress, intestinal disorders, and low body mass index. Recognition of this might hold the key to improving long-term management of NERD.